Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
Sporanox	O
/	O
Ace	O
Inhibitors	O
/	O
Penicillins	O
Attending:	O
___.	O
Chief	O
Complaint:	O
altered	B-Delirium
mental	B-Delirium
status,	B-Delirium
acute	O
on	O
chronic	O
renal	O
failure	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Colonoscopy	O
and	O
esophagogastroduodenoscopy	O
___	O
Hemodialysis	O
Right	O
brachial	O
venous	O
PICC	O
placement	O
___	O
History	O
of	O
Present	O
Illness:	O
(per	O
admission	O
note	O
___	O
by	O
Dr.	O
___	O
___	O
yo	O
male	O
with	O
PMH	O
sig	O
for	O
CRI	O
___	O
kidney	O
transplant	O
in	O
___,	O
CHF	O
(35-40%),	O
CAD	O
___	O
CABG,	O
COPD,	O
transferred	O
from	O
___	O
ICU	O
for	O
concern	O
of	O
ARF	O
and	O
change	B-Delirium
in	B-Delirium
mental	B-Delirium
status.	B-Delirium
Pt	O
recently	O
discharged	O
from	O
___	O
on	O
___	O
and	O
___	O
for	O
worsening	O
dyspnea	O
thought	O
to	O
be	O
secondary	O
to	O
CHF	O
and	O
COPD	O
exacerbation.	O
He	O
sent	O
to	O
rehab	O
on	O
40mg	O
IV	O
lasix,	O
10	O
day	O
course	O
of	O
levofloxacin,	O
and	O
prednisone	O
taper.	O
He	O
presented	O
on	O
___	O
with	O
worsening	O
SOB	O
thought	O
to	O
be	O
secondary	O
to	O
COPD	O
exacerbation	O
and/or	O
CHF	O
exacerbation.	O
There	O
was	O
also	O
quesiton	O
of	O
LL	O
lobe	O
pneumonia	B-Lower_respiratory_tract_infection
and	O
was	O
started	O
on	O
Vancomycin/levofloxacin	O
and	O
IV	O
steriods.	O
He	O
was	O
also	O
diuresed	O
with	O
IV	O
lasix.	O
His	O
respiratory	O
status	O
improved	O
with	O
these	O
interventions.	O
CXR	O
was	O
consistent	O
with	O
CHF	O
exacerbation	O
and	O
BNP	O
was	O
>15,000.	O
U/S	O
of	O
the	O
abdomen	O
was	O
performed	O
that	O
was	O
unremarkable	O
and	O
___	O
were	O
negative	O
for	O
DVT.	O
CE	O
negative	O
x3.	O
His	O
renal	O
function	O
ranged	O
btw	O
3.5-3.6.	O
The	O
patient	O
also	O
received	O
1U	O
pRBC	O
for	O
Hb	O
8.	O
The	O
patient	O
had	O
increasing	O
somnolence	O
and	O
given	O
concern	O
of	O
tranplant	O
failure	O
he	O
was	O
transferred	O
to	O
___.	O
.	O
On	O
the	O
floor	O
the	O
patient	O
was	O
unable	O
to	O
give	O
a	O
clear	O
history.	O
He	O
was	O
oriented	B-Delirium
x3,	O
but	O
was	O
slow	O
and	O
confused	B-Delirium
regarding	O
his	O
symptoms	O
and	O
clinical	O
course.	O
He	O
denied	O
fevers,	O
chills,	O
chest	O
pain,	O
SOB,	O
or	O
pain.	O
Past	O
Medical	O
History:	O
ESRD	O
___	O
FSGS	O
___	O
CRT	O
___	O
c/b	O
chronic	O
rejection	O
CAD	O
___	O
3V	O
CABG	O
___	O
(SVG	O
to	O
OM,	O
SVG	O
to	O
PDA,	O
LIMA	O
to	O
LAD)	O
Chronic	O
diastolic	O
CHF	O
Mild	O
MR	O
COPD	O
___.	O
coli	O
pelvic	O
abscess	O
HTN	O
Hyperlipidemia	O
Angiodysplasias	O
in	O
stomach,	O
duodenum	O
and	O
colon	O
VZV	O
c/b	O
PHN	O
Gout	O
BCC	O
Umbilical	O
hernia	O
repair	O
BPH	O
Social	O
History:	O
___	O
Family	O
History:	O
Father	O
had	O
CAD	O
and	O
died	O
of	O
a	O
CVA.	O
Mother	O
died	O
of	O
an	O
unknown	O
cancer	O
that	O
had	O
metastasized	O
to	O
the	O
liver.	O
One	O
brother	O
has	O
CAD.	O
Physical	O
Exam:	O
ADMISSION	O
PHYSICAL	O
EXAM	O
(per	O
admission	O
note	O
___	O
by	O
Dr.	O
___:	O
V/S:	O
T:96.1	O
BP:160/62	O
HR:61	O
RR:10	O
O2	O
98%	O
4L	O
Gen:	O
NAD/	O
pt	O
somnolent,	O
slow	O
to	O
respond	O
to	O
questions,	O
difficulty	O
concentrating,	O
orient	B-Delirium
x3.	O
Pt	O
stares	O
off	O
into	O
space	O
HEENT:	O
AT/NC,	O
PERRLA,	O
EOMI,	O
anicteric,	O
no	O
conjuctival	O
pallor,	O
MMM,	O
clear	O
oropharynx,	O
no	O
erythema,	O
no	O
exudates	O
no	O
rhinorrhea/	O
discharge,	O
no	O
sinus	O
tenderness	O
NECK:	O
supple,	O
trachea	O
midline,	O
no	O
LAD,	O
no	O
thyromegaly	O
LUNG:	O
+	O
crackles	O
to	O
mid	O
lung	O
fields	O
CV:	O
S1&S2,	O
RRR,	O
II/VI	O
SEM	O
no	O
G/M	O
JVD:	O
5cm	O
Carotid:	O
no	O
bruit	O
ABD:	O
Soft/+BS/	O
NT/	O
ND/no	O
rebound/	O
no	O
guarding/	O
palpable	O
transplant	O
kidney	O
in	O
RLQ	O
EXT:	O
No	O
C/C/	O
+___dema,	O
+asterixsis	O
+___P,	O
___	O
b/l	O
&	O
symetrical	O
NEURO:	O
AAOx3,	B-Delirium
although	O
slow	O
to	O
answer	O
questions.	O
poor	O
concentration	O
CN	O
II-XII	O
grossly	O
intact	O
and	O
non-focal	O
b/l	O
___	O
strength	O
in	O
upper	O
and	O
lower	O
ext	O
b/l	O
Sensation	O
to	O
pain,	O
temp,	O
position	O
intact	O
b/l	O
poor	O
finger/nose,	O
poor	O
rapid/alternating	O
coordination	O
deferred	O
gait.	O
Pertinent	O
Results:	O
___	O
5:00	O
pm	O
BLOOD	O
CULTURE	O
**FINAL	O
REPORT	O
___	O
Blood	O
Culture,	O
Routine	O
(Final	O
___:	O
NO	O
GROWTH.	O
.	O
___	O
5:15	O
pm	O
URINE	O
Source:	O
Catheter.	O
**FINAL	O
REPORT	O
___	O
URINE	O
CULTURE	O
(Final	O
___:	O
NO	O
GROWTH.	O
.	O
___	O
5:15	O
pm	O
URINE	O
**FINAL	O
REPORT	O
___	O
Legionella	O
Urinary	O
Antigen	O
(Final	O
___:	O
NEGATIVE	O
FOR	O
LEGIONELLA	O
SEROGROUP	O
1	O
ANTIGEN.	O
.	O
Cardiology	O
ReportECGStudy	O
Date	O
of	O
___	O
10:49:48	O
___	O
Sinus	O
rhythm.	O
Probable	O
left	O
ventricular	O
hypertrophy	O
with	O
repolarization	O
change.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
no	O
change.	O
.	O
___	O
CXR	O
FINDINGS:	O
In	O
comparison	O
with	O
study	O
of	O
___,	O
there	O
is	O
increasing	O
size	O
of	O
the	O
cardiac	O
silhouette	O
given	O
the	O
PA	O
rather	O
than	O
AP	O
view.	O
Increasing	O
pulmonary	O
vascular	O
congestion.	O
Silhouetting	O
of	O
one	O
of	O
the	O
hemidiaphragms	O
is	O
consistent	O
with	O
lower	O
lung	O
consolidation.	O
.	O
___	O
RENAL	O
U/S	O
Transplant	O
renal	O
kidney	O
in	O
the	O
right	O
lower	O
quadrant	O
measures	O
9.9	O
cm,	O
and	O
has	O
unremarkable	O
gray-scale	O
appearance.	O
There	O
is	O
no	O
hydronephrosis	O
or	O
mass.	O
There	O
is	O
no	O
perinephric	O
fluid	O
collection.	O
Color	O
Doppler	O
evaluation	O
of	O
the	O
transplant	O
renal	O
vasculature	O
shows	O
normal	O
flow	O
and	O
waveforms,	O
with	O
resistive	O
indices	O
ranging	O
from	O
0.7	O
to	O
0.75	O
in	O
the	O
segmental	O
arterial	O
branches.	O
Diastolic	O
flow	O
in	O
the	O
main	O
renal	O
artery	O
is	O
very	O
slightly	O
diminished,	O
but	O
main	O
renal	O
artery	O
waveform	O
is	O
otherwise	O
normal,	O
with	O
brisk	O
systolic	O
upstroke.	O
Main	O
renal	O
vein	O
has	O
normal	O
flow	O
and	O
waveforms.	O
IMPRESSION:	O
Unremarkable	O
transplant	O
renal	O
ultrasound.	O
.	O
___	O
CXR	O
FINDINGS:	O
As	O
compared	O
to	O
the	O
previous	O
radiograph,	O
the	O
pre-existing	O
pulmonary	O
edema	O
has	O
markedly	O
increased	O
in	O
severity.	O
There	O
is	O
now	O
clear	O
evidence	O
of	O
moderate-to-massive	O
intra-alveolar	O
and	O
interstitial	O
fluid	O
accumulation.	O
The	O
size	O
of	O
the	O
cardiac	O
silhouette	O
and	O
the	O
absence	O
of	O
pleural	O
effusions	O
is	O
unchanged.	O
There	O
is	O
no	O
evidence	O
of	O
focal	O
parenchymal	O
opacity	O
suggestive	O
of	O
pneumonia.	O
.	O
___	O
TTE	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
top	O
normal/borderline	O
dilated.	O
There	O
is	O
moderate	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
moderate	O
hypokinesis	O
of	O
the	O
septum	O
and	O
mild	O
hypokinesis	O
of	O
the	O
basal	O
to	O
mid	O
inferior	O
segments.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(PCWP>18mmHg).	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal.	O
The	O
aortic	O
valve	O
leaflets	O
(3)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present.	O
No	O
aortic	O
regurgitation	O
is	O
seen.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
Mild	O
(1+)	O
mitral	O
regurgitation	O
is	O
seen.	O
[Due	O
to	O
acoustic	O
shadowing,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
may	O
be	O
significantly	O
UNDERestimated.]	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
There	O
is	O
no	O
pericardial	O
effusion.	O
IMPRESSION:	O
Borderline	O
dilatation	O
of	O
the	O
left	O
ventricle	O
with	O
regional	O
LV	O
systolic	O
dysfunction.	O
Diastolic	O
dysfunction.	O
Mild	O
mitral	O
regurgitation.	O
Mild	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
Compared	O
with	O
the	O
prior	O
study	O
(images	O
reviewed)	O
of	O
___,	O
wall	O
motion	O
abnormalities	O
are	O
probably	O
new	O
(prior	O
echo	O
images	O
were	O
suboptimal).	O
Diastolic	O
dysfunction	O
can	O
now	O
be	O
clearly	O
determined.	O
The	O
degree	O
of	O
mitral	O
regurgitation	O
has	O
increased	O
slightly.	O
.	O
___	O
CXR	O
FINDINGS:	O
As	O
compared	O
to	O
the	O
previous	O
examination,	O
the	O
signs	O
suggestive	O
of	O
pulmonary	O
edema	O
have	O
moderately	O
decreased.	O
They	O
are,	O
however,	O
still	O
present.	O
Unchanged	O
moderate	O
cardiomegaly.	O
No	O
evidence	O
of	O
right	O
pleural	O
effusion,	O
the	O
left	O
sinus	O
is	O
not	O
shown	O
on	O
today's	O
image.	O
.	O
___	O
CXR	O
AP	O
PORTABLE	O
CHEST:	O
The	O
heart	O
size	O
is	O
mildly	O
enlarged	O
but	O
stable.	O
The	O
aorta	O
is	O
mildly	O
tortuous	O
with	O
calcifications	O
noted	O
of	O
the	O
arch.	O
The	O
patient	O
is	O
status	O
post	O
sternotomy.	O
Pulmonary	O
edema	O
has	O
significantly	O
improved	O
and	O
there	O
is	O
now	O
mild	O
residual	O
interstitial	O
edema.	O
There	O
is	O
mild	O
subsegmental	O
atelectasis	O
at	O
the	O
left	O
lung	O
base	O
on	O
this	O
image	O
which	O
does	O
not	O
fully	O
include	O
the	O
costophrenic	O
sulcus.	O
There	O
is	O
no	O
pneumothorax	O
or	O
evidence	O
of	O
pneumonia.	O
IMPRESSION:	O
Significant	O
improvement	O
in	O
pulmonary	O
edema	O
with	O
now	O
mild	O
residual	O
interstitial	O
edema.	O
Mild	O
subsegmental	O
atelectasis	O
at	O
the	O
left	O
lung	O
base.	O
.	O
___	O
LOWER	O
EXTREMITY	O
DOPPLER	O
U/S	O
FINDINGS:	O
Gray-scale	O
and	O
color	O
Doppler	O
images	O
of	O
the	O
left	O
and	O
right	O
common	O
femoral,	O
superficial	O
femoral,	O
popliteal	O
and	O
peroneal	O
veins	O
were	O
performed.	O
There	O
is	O
absence	O
of	O
color	O
flow	O
and	O
non-compressibility	O
of	O
the	O
left	O
peroneal	O
vein,	O
otherwise,	O
there	O
is	O
normal	O
color	O
flow,	O
compressibility	O
and	O
augmentation.	O
Left	O
Bakers'	O
cyst	O
is	O
seen.	O
IMPRESSION:	O
Findings	O
compatible	O
with	O
thrombus	O
in	O
the	O
left	O
peroneal	O
vein.	O
.	O
___	O
TTE	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
top	O
normal/borderline	O
dilated.	O
There	O
is	O
mild	O
regional	O
systolic	O
dysfunction	O
with	O
hypokinesis	O
of	O
the	O
inferior	O
wall	O
and	O
likely	O
the	O
inferior	O
septum	O
(image	O
quality	O
suboptimal).	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
mildly	O
depressed	O
(LVEF=	O
40	O
%).	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(PCWP>18mmHg).	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal.	O
The	O
aortic	O
valve	O
leaflets	O
(3)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present.	O
There	O
is	O
no	O
aortic	O
regurgitation.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
Mild	O
to	O
moderate	O
(___)	O
mitral	O
regurgitation	O
is	O
seen.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
indeterminate.	O
There	O
is	O
no	O
pericardial	O
effusion.	O
IMPRESSION:	O
Suboptimal	O
image	O
quality.	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
focal	O
regional	O
systolic	O
dysfunction	O
consistent	O
with	O
coronary	O
artery	O
disease.	O
Mild	O
to	O
moderate	O
aortic	O
regurgitation.	O
Compared	O
with	O
the	O
prior	O
study	O
(images	O
reviewed)	O
of	O
___,	O
the	O
estimated	O
pulmonary	O
artery	O
pressures	O
are	O
now	O
indeterminate.	O
.	O
___	O
LOWER	O
EXTREMITY	O
DOPPLER	O
U/S	O
FINDINGS:	O
Grayscale,	O
color	O
and	O
Doppler	O
sonograms	O
of	O
the	O
left	O
common	O
femoral,	O
superficial	O
femoral,	O
popliteal	O
and	O
tibial	O
veins	O
were	O
performed.	O
There	O
is	O
normal	O
flow,	O
compression	O
and	O
augmentation	O
seen	O
in	O
all	O
of	O
the	O
vessels	O
including	O
the	O
two	O
left	O
peroneal	O
vessels.	O
No	O
DVT	O
is	O
identified	O
today.	O
Again	O
seen	O
is	O
a	O
___	O
cyst	O
in	O
the	O
left	O
popliteal	O
fossa.	O
IMPRESSION:	O
No	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
in	O
the	O
left	O
leg	O
with	O
resolution	O
of	O
the	O
thrombosis	O
recently	O
seen	O
in	O
the	O
left	O
peroneal	O
pain.	O
Left	O
___	O
cyst.	O
.	O
___	O
RENAL	O
TRANSPLANT	O
U/S	O
FINDINGS:	O
The	O
renal	O
transplant	O
is	O
identified	O
in	O
the	O
right	O
lower	O
quadrant	O
and	O
measures	O
10.1	O
cm	O
in	O
length.	O
There	O
is	O
no	O
hydronephrosis	O
and	O
no	O
perinephric	O
collections	O
are	O
identified.	O
DOPPLER	O
EXAMINATION:	O
Color	O
Doppler	O
and	O
pulse-wave	O
Doppler	O
images	O
were	O
obtained.	O
Abnormal	O
arterial	O
waveforms	O
are	O
identified	O
in	O
the	O
main	O
renal	O
artery	O
and	O
in	O
the	O
intraparenchymal	O
renal	O
arteries.	O
There	O
is	O
no	O
diastolic	O
flow	O
identified	O
on	O
any	O
of	O
the	O
tracings.	O
This	O
appearance	O
is	O
consistent	O
with	O
rejection.	O
Appropriate	O
venous	O
flow	O
is	O
identified	O
in	O
the	O
main	O
renal	O
vein.	O
IMPRESSION:	O
1.	O
Abnormal	O
arterial	O
waveforms	O
in	O
the	O
transplant	O
kidney	O
with	O
no	O
diastolic	O
flow	O
identified.	O
This	O
appearance	O
is	O
consistent	O
with	O
rejection.	O
Normal	O
venous	O
flow	O
identified	O
in	O
the	O
hilum	O
of	O
the	O
transplant	O
kidney.	O
2.	O
No	O
hydronephrosis	O
and	O
no	O
perinephric	O
collections	O
identified.	O
Brief	O
Hospital	O
Course:	O
#DVT/PE	O
-	O
Lower	O
extremity	O
doppler	O
U/S	O
on	O
___	O
revealed	O
thrombus	O
in	O
the	O
left	O
peroneal	O
vein.	O
The	O
patient	O
was	O
started	O
on	O
heparin	O
gtt.	O
Due	O
to	O
concomitant	O
hypoxemia,	O
a	O
presumptive	O
diagnosis	O
of	O
PE	O
was	O
made.	O
V/Q	O
scan	O
was	O
deferred	O
due	O
to	O
underlying	O
COPD	O
and	O
a	O
baseline	O
abnormal	O
CXR,	O
and	O
CTA	O
chest	O
was	O
deferred	O
due	O
to	O
renal	O
insufficiency.	O
Repeat	O
U/S	O
___	O
showed	O
resolution	O
of	O
DVT.	O
Coumadin	O
was	O
started	O
___	O
after	O
hematocrit	O
had	O
remained	O
stable	O
(goal	O
INR	O
___.	O
He	O
will	O
likely	O
require	O
___	O
months	O
of	O
therapeutic	O
anticoagulation.	O
Goal	O
INR	O
is	O
at	O
the	O
lower	O
end	O
of	O
the	O
therapeutic	O
range	O
due	O
to	O
his	O
GI	O
AVM's,	O
prior	O
bleeding	O
and	O
risk	O
for	O
re-bleeding.	O
.	O
#Acute	O
on	O
chronic	O
systolic	O
and	O
diastolic	O
heart	O
failure	O
-	O
Attributed	O
to	O
a	O
combination	O
of	O
discontinuation	O
of	O
diuretic	O
medication,	O
alterations	O
in	O
the	O
antihypertensive	O
regimen,	O
and	O
acute	O
on	O
chronic	O
renal	O
insufficiency.	O
Treated	O
with	O
hemodialysis	O
and	O
medical	O
diuresis.	O
TTE	O
___	O
revealed	O
LVEF	O
35-40%,	O
moderate	O
septal	O
hypokinesis,	O
and	O
mild	O
hypokinesis	O
of	O
the	O
basal	O
to	O
mid	O
inferior	O
segments.	O
He	O
demonstrated	O
adequate	O
room	O
air	O
oxygenation	O
prior	O
to	O
discharge.	O
He	O
will	O
be	O
discharged	O
on	O
aspirin,	O
metoprolol,	O
furosemide,	O
metolazone,	O
and	O
isosorbide	O
mononitrate	O
for	O
afterload	O
reduction.	O
An	O
ACEi	O
was	O
not	O
prescribed	O
due	O
to	O
allergy.	O
He	O
was	O
advised	O
to	O
record	O
daily	O
weights	O
and	O
to	O
adhere	O
to	O
a	O
low	O
sodium	O
diet	O
with	O
2	O
L	O
fluid	O
restriction.	O
.	O
#Acute	O
on	O
chronic	O
renal	O
insufficiency	O
-	O
Due	O
to	O
intravascular	O
volume	O
depletion	O
in	O
the	O
setting	O
of	O
CHF	O
exacerbation	O
and	O
antihypertensive	O
therapy,	O
as	O
evidenced	O
by	O
an	O
extremely	O
low	O
urinary	O
sodium	O
on	O
admission.	O
Initial	O
renal	O
ultrasound	O
was	O
unremarkable,	O
but	O
repeat	O
exam	O
on	O
___	O
revealed	O
evidence	O
of	O
rejection.	O
Serum	O
tacrolimus	O
level	O
was	O
therapeutic.	O
He	O
was	O
advised	O
to	O
adhere	O
to	O
a	O
low	O
sodium/potassium/phosphorus	O
diet.	O
Per	O
the	O
Transplant	O
Nephrology	O
team,	O
the	O
initial	O
plan	O
will	O
be	O
twice	O
weekly	O
HD	O
when	O
he	O
is	O
discharged	O
to	O
the	O
rehabilitation	O
facility.	O
He	O
has	O
a	O
f/u	O
app't	O
at	O
his	O
primary	O
nephrologist's	O
office	O
in	O
4	O
weeks	O
(Dr.	O
___.	O
At	O
that	O
time,	O
he	O
will	O
be	O
seeing	O
the	O
NP,	O
who	O
will	O
make	O
arrangements	O
for	O
an	O
app't	O
with	O
Dr.	O
___	O
___	O
after	O
(this	O
was	O
due	O
to	O
scheduling	O
availability).	O
.	O
#Acute	O
blood	O
loss	O
anemia	O
-	O
The	O
patient	O
had	O
guaiac	O
positive	O
stools	B-Lower_gastrointestinal_haemorrhage
without	O
overt	O
evidence	O
of	O
bleeding.	B-Lower_gastrointestinal_haemorrhage
The	O
patient	O
was	O
transfused	O
a	O
total	O
5	O
U	O
PRBC.	O
He	O
was	O
treated	O
with	O
IV	O
iron	O
and	O
erythropoetin.	O
Colonoscopy	O
___	O
revealed	O
a	O
proximal	O
ascending	O
colon	O
AVM	O
which	O
was	O
treated	O
with	O
argon	O
thermal	O
therapy.	O
Endoscopy	O
on	O
that	O
date	O
showed	O
non-bleeding	O
erosions	O
in	O
the	O
stomach	O
and	O
proximal	O
jejunum.	O
He	O
will	O
continue	O
on	O
twice	O
daily	O
PPI.	O
Outpatient	O
capsule	O
endoscopy	O
was	O
recommended.	O
Has	O
been	O
on	O
IV	O
iron	O
therapy	O
and	O
will	O
need	O
3	O
more	O
days	O
(started	O
___	O
for	O
an	O
8	O
day	O
course).	O
Please	O
remove	O
his	O
R	O
PICC	O
line	O
after	O
IV	O
iron	O
therapy	O
is	O
completed.	O
.	O
#Toxic	O
encephalopathy	O
-	O
Attributed	O
to	O
effects	O
of	O
medications,	O
as	O
mental	O
status	O
improved	O
after	O
the	O
discontinuation	O
of	O
prednisone	O
and	O
oral	O
narcotics.	O
Delirium	B-Delirium
did	O
not	O
seem	O
to	O
improve	O
following	O
hemodialysis,	O
making	O
uremic	O
encephalopathy	O
unlikely.	O
Infectious	O
workup	O
was	O
unremarkable.	O
ABG	O
was	O
not	O
suggestive	O
of	O
profound	O
hypercarbia	O
or	O
hypoxia.	O
EKG	O
did	O
not	O
reveal	O
evidence	O
of	O
new	O
ischemia	O
or	O
arrhythmia.	O
Electrolytes,	O
glucose,	O
and	O
LFT's	O
were	O
within	O
normal	O
limits.	O
Mental	B-Delirium
status	B-Delirium
returned	O
to	O
baseline	B-Delirium
prior	O
to	O
discharge,	O
as	O
corroborated	O
by	O
the	O
patient's	O
wife.	O
.	O
#Status	O
post	O
cadaveric	O
renal	O
transplant	O
-	O
Sirolimus	O
was	O
changed	O
to	O
tacrolimus	O
at	O
the	O
recommendation	O
of	O
the	O
transplant	O
nephrology	O
team.	O
Serum	O
tacrolimus	O
level	O
was	O
therapeutic.	O
Continued	O
MMF	O
and	O
bactrim	O
prophylaxis.	O
The	O
patient	O
will	O
be	O
seen	O
in	O
close	O
follow	O
up	O
in	O
transplant	O
clinic	O
following	O
discharge.	O
.	O
#Post-herpetic	O
neuralgia	O
-	O
Continued	O
fentanyl	O
patch	O
and	O
nortriptyline.	O
At	O
the	O
recommendation	O
of	O
the	O
chronic	O
pain	O
service,	O
lyrica	O
was	O
added	O
with	O
subsequent	O
resolution	O
of	O
symptoms.	O
.	O
#Mood	O
disorder	O
-	O
The	O
patient	O
was	O
seen	O
in	O
consultation	O
by	O
psychiatry	O
who	O
recommended	O
the	O
addition	O
of	O
mirtazapine	O
with	O
a	O
subsequent	O
improvement	O
in	O
mood	O
and	O
sleep.	O
It	O
was	O
recommended	O
that	O
the	O
patient	O
consider	O
formal	O
neuropsychological	O
testing	O
in	O
the	O
future	O
to	O
evaluate	O
for	O
memory	O
or	O
cognitive	O
deficits.	O
.	O
#Coronary	O
artery	O
disease	O
-	O
No	O
acute	O
issues.	O
Aspirin,	O
betablocker,	O
and	O
statin	O
were	O
continued,	O
as	O
above.	O
.	O
#Chronic	O
obstructive	O
pulmonary	O
disease	O
-	O
No	O
acute	O
issues.	O
Continued	O
advair	O
and	O
nebulized	O
bronchodilators	O
as	O
needed.	O
.	O
#Hypertension	O
-	O
Blood	O
pressure	O
was	O
well-controlled	O
on	O
a	O
regimen	O
of	O
metoprolol	O
and	O
isosorbide	O
mononitrate.	O
.	O
#Dyslipidemia	O
-	O
Continued	O
simvastatin.	O
Medications	O
on	O
Admission:	O
Ferrous	O
Gluconate	O
325mg	O
BID	O
Lyrica	O
200mg	O
daily	O
Restoril	O
15mg	O
qHS	O
ASA	O
81mg	O
daily	O
Prednisone	O
5mg	O
daily	O
Zocor	O
40mg	O
daily	O
Florastor	O
250mg	O
BID	O
calcitriol	O
0.5	O
mg	O
qhs	O
CellCept	O
500mg	O
BID	O
Hydral	O
75mg	O
BID	O
Lopressor	O
50mg	O
daily	O
Advair	O
BID	O
Albuterol	O
2	O
puffs	O
QID	O
Atrovent	O
2	O
sprays	O
QID	O
Bactrim	O
DS	O
0.5	O
tab	O
Daily	O
Norvasc	O
10mg	O
daily	O
Sirolimus	O
1mg	O
daily	O
Pamelor	O
10mg	O
daily	O
Imdur	O
30mg	O
daily	O
Discharge	O
Medications:	O
1.	O
Mycophenolate	O
Mofetil	O
500	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
2.	O
Fluticasone-Salmeterol	O
250-50	O
mcg/Dose	O
Disk	O
with	O
Device	O
Sig:	O
One	O
(1)	O
Disk	O
with	O
Device	O
Inhalation	O
BID	O
(2	O
times	O
a	O
day).	O
3.	O
Trimethoprim-Sulfamethoxazole	O
80-400	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
4.	O
Senna	O
8.6	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day)	O
as	O
needed.	O
5.	O
Albuterol	O
Sulfate	O
2.5	O
mg	O
/3	O
mL	O
(0.083	O
%)	O
Solution	O
for	O
Nebulization	O
Sig:	O
One	O
(1)	O
INH	O
Inhalation	O
every	O
___	O
hours	O
as	O
needed	O
for	O
shortness	O
of	O
breath	O
or	O
wheezing.	O
6.	O
Ipratropium	O
Bromide	O
0.02	O
%	O
Solution	O
Sig:	O
One	O
(1)	O
INH	O
Inhalation	O
Q6H	O
(every	O
6	O
hours)	O
as	O
needed	O
for	O
shortness	O
of	O
breath	O
or	O
wheezing.	O
7.	O
Simvastatin	O
40	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
8.	O
Fentanyl	O
50	O
mcg/hr	O
Patch	O
72	O
hr	O
Sig:	O
One	O
(1)	O
Patch	O
72	O
hr	O
Transdermal	O
Q72H	O
(every	O
72	O
hours).	O
9.	O
Bisacodyl	O
5	O
mg	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
Sig:	O
Two	O
(2)	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
PO	O
DAILY	O
(Daily)	O
as	O
needed	O
for	O
constipation.	O
10.	O
Lidocaine	O
5	O
%(700	O
mg/patch)	O
Adhesive	O
Patch,	O
Medicated	O
Sig:	O
One	O
(1)	O
Adhesive	O
Patch,	O
Medicated	O
Topical	O
Q12H	O
(every	O
12	O
hours)	O
as	O
needed	O
for	O
pain:	O
Remove	O
after	O
12	O
hours.	O
.	O
11.	O
Acetaminophen	O
500	O
mg	O
Tablet	O
Sig:	O
___	O
Tablets	O
PO	O
every	O
six	O
(6)	O
hours	O
as	O
needed	O
for	O
fever	O
or	O
pain.	O
12.	O
Isosorbide	O
Mononitrate	O
30	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig:	O
Two	O
(2)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
DAILY	O
(Daily):	O
hold	O
for	O
sbp<100.	O
13.	O
Mirtazapine	O
15	O
mg	O
Tablet	O
Sig:	O
0.5	O
Tablet	O
PO	O
HS	O
(at	O
bedtime).	O
14.	O
Pregabalin	O
75	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
15.	O
Calcitriol	O
0.25	O
mcg	O
Capsule	O
Sig:	O
Two	O
(2)	O
Capsule	O
PO	O
DAILY	O
(Daily).	O
16.	O
Amlodipine	O
5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
17.	O
Pantoprazole	O
40	O
mg	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
Sig:	O
One	O
(1)	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
PO	O
Q12H	O
(every	O
12	O
hours).	O
18.	O
Florastor	O
250	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
twice	O
a	O
day.	O
19.	O
Senna	O
8.6	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
20.	O
Polyethylene	O
Glycol	O
3350	O
100	O
%	O
Powder	O
Sig:	O
Seventeen	O
(17)	O
grams	O
PO	O
DAILY	O
(Daily).	O
21.	O
Na	O
Ferric	O
Gluc	O
Cplx	O
in	O
Sucrose	O
12.5	O
mg/mL	O
Solution	O
Sig:	O
One	O
(1)	O
Intravenous	O
DAILY	O
(Daily)	O
for	O
3	O
days.	O
22.	O
Lactulose	O
10	O
gram/15	O
mL	O
Syrup	O
Sig:	O
Thirty	O
(30)	O
ML	O
PO	O
Q8H	O
(every	O
8	O
hours)	O
as	O
needed	O
for	O
constipation.	B-Constipation
23.	O
Metoprolol	O
Tartrate	O
25	O
mg	O
Tablet	O
Sig:	O
0.5	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
24.	O
B	O
Complex-Vitamin	O
C-Folic	O
Acid	O
1	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Cap	O
PO	O
DAILY	O
(Daily).	O
25.	O
Metolazone	O
5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
26.	O
Trazodone	O
50	O
mg	O
Tablet	O
Sig:	O
0.5	O
Tablet	O
PO	O
HS	O
(at	O
bedtime)	O
as	O
needed	O
for	O
insomnia.	O
27.	O
Furosemide	O
80	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
28.	O
Epoetin	O
Alfa	O
4,000	O
unit/mL	O
Solution	O
Sig:	O
Two	O
(2)	O
mL	O
Injection	O
QMOWEFR	O
(___).	O
29.	O
Aspirin	O
81	O
mg	O
Tablet,	O
Chewable	O
Sig:	O
One	O
(1)	O
Tablet,	O
Chewable	O
PO	O
DAILY	O
(Daily).	O
30.	O
Warfarin	O
5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
___.	O
31.	O
Calcitriol	O
0.25	O
mcg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
DAILY	O
(Daily).	O
32.	O
Tacrolimus	O
0.5	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
Q12H	O
(every	O
12	O
hours).	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Primary	O
1)	O
Acute	O
on	O
chronic	O
systolic	O
and	O
diastolic	O
heart	O
failure	O
2)	O
Acute	O
on	O
chronic	O
renal	O
insufficiency	O
3)	O
Pulmonary	O
embolus	O
4)	O
Deep	O
vein	O
thrombosis	O
5)	O
Acute	O
blood	O
loss	O
anemia	O
6)	O
Colonic	O
angiodysplasia	O
7)	O
Toxic	O
encephalopathy	O
8)	O
Post-herpetic	O
neuralgia	O
9)	O
Mood	O
disorder	O
Secondary	O
1)	O
Status	O
post	O
cadaveric	O
renal	O
transplant	O
2)	O
Chronic	O
allograft	O
nephropathy	O
3)	O
Coronary	O
artery	O
disease	O
4)	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
5)	O
Hypertension	O
6)	O
Dyslipidemia	O
Discharge	O
Condition:	O
-	O
stable	O
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
with	O
shortness	O
of	O
breath	O
in	O
the	O
setting	O
of	O
worsening	O
renal	O
failure	O
and	O
congestive	O
heart	O
failure.	O
Fluid	O
was	O
removed	O
with	O
hemodialysis	O
and	O
diuretic	O
medication.	O
Please	O
record	O
your	O
weight	O
daily	O
and	O
contact	O
your	O
physician	O
if	O
your	O
weight	O
increases	O
by	O
more	O
than	O
3	O
pounds.	O
Please	O
adhere	O
to	O
a	O
diet	O
containing	O
less	O
2	O
grams	O
of	O
sodium,	O
2	O
grams	O
of	O
potassium,	O
and	O
1	O
gram	O
of	O
phosphorus	O
daily.	O
Please	O
adhere	O
to	O
a	O
2	O
liter	O
daily	O
fluid	O
restriction.	O
You	O
had	O
a	O
colonoscopy	O
which	O
showed	O
an	O
arteriovenous	O
malformation	O
(AVM)	O
in	O
the	O
large	O
intestine.	O
This	O
was	O
treated	O
with	O
argon	O
thermal	O
therapy.	O
Upper	O
endoscopy	O
showed	O
multiple	O
non-bleeding	O
erosions	O
in	O
the	O
stomach	O
and	O
small	O
intestine.	O
Please	O
call	O
___	O
to	O
schedule	O
an	O
outpatient	O
capsule	O
endoscopy	O
study	O
at	O
your	O
earliest	O
convenience.	O
The	O
following	O
medication	O
changes	O
were	O
recommended:	O
1)	O
Sirolimus	O
was	O
changed	O
to	O
a	O
similar	O
medication	O
tacrolimus	O
0.5	O
mg	O
twice	O
daily.	O
2)	O
Lasix	O
was	O
increased,	O
but	O
at	O
discharge	O
was	O
back	O
at	O
80	O
mg	O
twice	O
daily.	O
3)	O
Isosorbide	O
mononitrate	O
(Imdur)	O
was	O
increased	O
to	O
60	O
mg	O
daily.	O
4)	O
Amlodipine	O
(Norvasc)	O
was	O
discontinued.	O
5)	O
Hydralazine	O
was	O
discontinued.	O
6)	O
Pregabalin	O
(Lyrica)	O
was	O
decreased	O
to	O
75	O
mg	O
twice	O
daily.	O
7)	O
Temazepam	O
(Restoril)	O
was	O
replaced	O
with	O
Mirtazapine	O
(Remeron).	O
8)	O
Pantoprazole	O
(Protonix)	O
was	O
increased	O
to	O
40	O
mg	O
twice	O
daily.	O
Please	O
call	O
your	O
physician	O
or	O
return	O
to	O
the	O
Emergency	O
Department	O
if	O
you	O
experience	O
fever,	O
chills,	O
sweats,	O
dizziness,	O
lightheadedness,	O
chest	O
pain,	O
palpitations,	O
cough,	O
wheezing,	O
shortness	O
of	O
breath,	O
abdominal	O
pain,	O
vomiting,	O
diarrhea,	O
bloody	B-Lower_gastrointestinal_haemorrhage
or	O
dark	B-Upper_gastrointestinal_haemorrhage
stools,	B-Upper_gastrointestinal_haemorrhage
or	O
difficulty	O
with	O
urination.	O
Followup	O
Instructions:	O
___	O

